Currently, semaglutide is approved by the Food and Drug Administration not only for T2DM management, to decrease cardiovascular events in adults with T2DM, and for chronic weight management for those with a BMI of ≥30 kg/m2 or ≥27 kg/m2 with at least 1 weight-related comorbidity Therefore, a significant portion of older adults may be prescribed GLP-1 receptor agonists considering that 29% of them have T2DM and 42.8% of them have a BMI of ≥30 kg/m2 [1,13]. Here, GLP1R is linked to type 2 diabetes mellitus.